Immunoadsorption Versus Plasma Exchange for Treatment of Guillain-Barré Syndrome (GBS) (IPET-GBS)

University of Ulm

Status: Enrolling

Conditions: GBS

Treatments: Device: Immunoadsorption; Device: Plasma Exchange

Study type: Observational

Funder types: Other; Industry

Identifiers

NCT04871035

IPET-GBS 1.2

Details and patient eligibility

About

This is an observations study evaluating safety and efficacy of immunoadsorption compared to plasma exchange in Guillain-Barré Syndrome.

Enrollment: 20 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Diagnosis of Guillain-Barré Syndrome according to the diagnostic criteria proposed by Doorn et al. (Clinical features, pathogenesis, and treatment of Guillain-Barré syndrome, Lancet neurology 2008)
• age 18 years or above

Exclusion criteria

• Clinical or laboratory (C-reactive protein 20 mg/l or above, or evidence of nitrite-positive urinary tract infection) evidence of manifest systemic infection
• Intake of angiotensin converting enzyme inhibitor within1 weeks before first treatment
• Other contraindications against immunoadsorption or plasma exchange

Trial design

20 participants in 2 patient groups

Immunoadsorption

Treatment:

Device: Immunoadsorption

Plasma Exchange

Treatment:

Device: Plasma Exchange